Eli Lilly becomes 1st healthcare company to hit $1 trillion valuation
Eli Lilly just made history as the first drug company to hit a $1 trillion market value, thanks to a huge boost from its diabetes and weight-loss drugs, Mounjaro and Zepbound.
The stock is up over 36% this year, showing how much investors believe in their new medicines addressing significant health issues.
Why does this matter?
Mounjaro quickly crossed $1 billion in sales, and Zepbound is riding the wave of demand for effective weight-loss treatments.
Both use tirzepatide, which targets two gut hormones, helping suppress appetite and improve how the body handles sugar and fat—giving Eli Lilly an edge in a booming market expected to top $150 billion by the early 2030s.
This milestone isn't just about money—it's about how breakthrough medicines are changing healthcare and what investors care about most.